Imatinib Mesylate Patent Expiration
Imatinib Mesylate is Used for treating tumors and gastrointestinal stromal tumors (GIST) in patients with CD117 positive unresectable or metastatic disease. It was first introduced by Novartis Pharmaceuticals Corp
Imatinib Mesylate Patents
Given below is the list of patents protecting Imatinib Mesylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Gleevec | US5521184 | Pyrimidine derivatives and processes for the preparation thereof |
Jan 04, 2015
(Expired) | Novartis |
| Gleevec |
US5521184 (Pediatric) | Pyrimidine derivatives and processes for the preparation thereof |
Jul 04, 2015
(Expired) | Novartis |
| Gleevec | US6894051 | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
May 23, 2019
(Expired) | Novartis |
| Gleevec |
US6894051 (Pediatric) | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Nov 23, 2019
(Expired) | Novartis |
| Gleevec | US6958335 | Treatment of gastrointestinal stromal tumors |
Dec 19, 2021
(Expired) | Novartis |
| Gleevec |
US6958335 (Pediatric) | Treatment of gastrointestinal stromal tumors |
Jun 19, 2022
(Expired) | Novartis |
| Gleevec | US7544799 | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jan 16, 2019
(Expired) | Novartis |
| Gleevec |
US7544799 (Pediatric) | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jul 16, 2019
(Expired) | Novartis |
| Gleevec | USRE43932 | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jan 16, 2019
(Expired) | Novartis |
| Gleevec | USRE43932 | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jul 16, 2018
(Expired) | Novartis |
| Gleevec |
USRE43932 (Pediatric) | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jan 16, 2019
(Expired) | Novartis |
| Gleevec |
USRE43932 (Pediatric) | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jul 16, 2019
(Expired) | Novartis |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Imatinib Mesylate Generics
Several generic applications have been filed for Imatinib Mesylate. The first generic version for Imatinib Mesylate was by Sun Pharmaceutical Industries Ltd and was approved on Dec 3, 2015. And the latest generic version is by Qilu Pharmaceutical Hainan Co Ltd and was approved on Jun 21, 2022.
Given below is the list of companies who have filed for Imatinib Mesylate generic.
1. MYLAN
Mylan Pharmaceuticals Inc has filed for 2 different strengths of generic version for Imatinib Mesylate. Given below are the details of the strengths of this generic introduced by Mylan.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 100MG BASE | tablet | Prescription | ORAL | AB | Jun 21, 2017 |
| EQ 400MG BASE | tablet | Prescription | ORAL | AB | Jun 21, 2017 |
2. DR REDDYS
Dr Reddys Laboratories Ltd has filed for 2 different strengths of generic version for Imatinib Mesylate. Given below are the details of the strengths of this generic introduced by Dr Reddys.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 100MG BASE | tablet | Prescription | ORAL | AB | Aug 13, 2018 |
| EQ 400MG BASE | tablet | Prescription | ORAL | AB | Aug 13, 2018 |
3. TEVA PHARMS USA
Teva Pharmaceuticals Usa has filed for 2 different strengths of generic version for Imatinib Mesylate. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 100MG BASE | tablet | Prescription | ORAL | AB | Aug 4, 2016 |
| EQ 400MG BASE | tablet | Prescription | ORAL | AB | Aug 4, 2016 |
4. QILU PHARM HAINAN
Qilu Pharmaceutical Hainan Co Ltd has filed for 2 different strengths of generic version for Imatinib Mesylate. Given below are the details of the strengths of this generic introduced by Qilu Pharm Hainan.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 100MG BASE | tablet | Prescription | ORAL | AB | Jun 21, 2022 |
| EQ 400MG BASE | tablet | Prescription | ORAL | AB | Jun 21, 2022 |
5. HIKMA
Hikma Pharmaceuticals Usa Inc has filed for 2 different strengths of generic version for Imatinib Mesylate. Given below are the details of the strengths of this generic introduced by Hikma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 400MG BASE | tablet | Discontinued | ORAL | N/A | Jul 13, 2018 |
| EQ 100MG BASE | tablet | Discontinued | ORAL | N/A | Jul 13, 2018 |
6. CHARTWELL RX
Chartwell Rx Sciences Llc has filed for 2 different strengths of generic version for Imatinib Mesylate. Given below are the details of the strengths of this generic introduced by Chartwell Rx.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 100MG BASE | tablet | Prescription | ORAL | AB | Jan 17, 2019 |
| EQ 400MG BASE | tablet | Prescription | ORAL | AB | Jan 17, 2019 |
7. SHILPA
Shilpa Medicare Ltd has filed for 2 different strengths of generic version for Imatinib Mesylate. Given below are the details of the strengths of this generic introduced by Shilpa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 100MG BASE | tablet | Prescription | ORAL | AB | Jan 17, 2019 |
| EQ 400MG BASE | tablet | Prescription | ORAL | AB | Jan 17, 2019 |
8. SUN PHARM
Sun Pharmaceutical Industries Ltd has filed for 2 different strengths of generic version for Imatinib Mesylate. Given below are the details of the strengths of this generic introduced by Sun Pharm.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 100MG BASE | tablet | Prescription | ORAL | AB | Dec 3, 2015 |
| EQ 400MG BASE | tablet | Prescription | ORAL | AB | Dec 3, 2015 |
9. AMNEAL PHARMS
Amneal Pharmaceuticals Of New York Llc has filed for 2 different strengths of generic version for Imatinib Mesylate. Given below are the details of the strengths of this generic introduced by Amneal Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 100MG BASE | tablet | Discontinued | ORAL | N/A | Feb 8, 2019 |
| EQ 400MG BASE | tablet | Discontinued | ORAL | N/A | Feb 8, 2019 |
10. BRECKENRIDGE
Breckenridge Pharmaceutical Inc has filed for 2 different strengths of generic version for Imatinib Mesylate. Given below are the details of the strengths of this generic introduced by Breckenridge.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 100MG BASE | tablet | Discontinued | ORAL | N/A | Feb 8, 2019 |
| EQ 400MG BASE | tablet | Discontinued | ORAL | N/A | Feb 8, 2019 |
11. ZYDUS PHARMS
Zydus Pharmaceuticals Usa Inc has filed for 2 different strengths of generic version for Imatinib Mesylate. Given below are the details of the strengths of this generic introduced by Zydus Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 100MG BASE | tablet | Prescription | ORAL | AB | Apr 8, 2020 |
| EQ 400MG BASE | tablet | Prescription | ORAL | AB | Apr 8, 2020 |
12. EUGIA PHARMA
Eugia Pharma Specialities Ltd has filed for 2 different strengths of generic version for Imatinib Mesylate. Given below are the details of the strengths of this generic introduced by Eugia Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 400MG BASE | tablet | Prescription | ORAL | AB | Jul 23, 2020 |
| EQ 100MG BASE | tablet | Prescription | ORAL | AB | Jul 23, 2020 |
13. APOTEX
Apotex Inc has filed for 2 different strengths of generic version for Imatinib Mesylate. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 100MG BASE | tablet | Prescription | ORAL | AB | Aug 5, 2016 |
| EQ 400MG BASE | tablet | Prescription | ORAL | AB | Aug 5, 2016 |
14. NATCO PHARMA LTD
Natco Pharma Ltd has filed for 2 different strengths of generic version for Imatinib Mesylate. Given below are the details of the strengths of this generic introduced by Natco Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 400MG BASE | tablet | Prescription | ORAL | AB | Mar 1, 2019 |
| EQ 100MG BASE | tablet | Prescription | ORAL | AB | Mar 1, 2019 |